[Comparison of superselective intraarterial fibrinolysis with conservative therapy. Use in patients with acute non-arteritic central retinal artery occlusion].
The results of conservative treatment for central retinal artery occlusion (CRAO) vary considerably and although local intraarterial fibrinolysis (LIF) is a promising treatment, outcomes have not been compared in randomized trials. The prospective randomized multicenter study by the European Assessment Group for Lysis in the Eye (EAGLE) is the first clinical trial to compare treatment outcomes of conservative standard treatment (CST) and LIF for acute non-arteritic CRAO. Patients (age 18-75 years) with CRAO present for less than 20 h and best-corrected visual acuity (BCVA) <0.5 logMAR were randomized to either CST or LIF group. Primary endpoint was BCVA after 1 month and secondary endpoint was safety. Mean BCVA (logMAR) improved significantly in both groups and did not differ between the groups. Because of similar efficacy and the higher rate of adverse events in the LIF group the study was halted after the first interim analysis. Due to the similar outcomes of the two therapies and the higher rate of adverse reactions associated with LIF superselective lysis cannot be recommended for the management of acute CRAO.
Wolf
A
A
Augenklinik der Ludwig-Maximilians-Universität, Mathildenstraße 8, 80336, München. armin.wolf@med.uni-muenchen.de
Schumacher
M
M
Neubauer
A S
AS
Schmoor
C
C
Gall
C
C
Jurklies
B
B
Wanke
I
I
Solymosi
L
L
Brückmann
H
H
Schmidt
D
D
Feltgen
N
N
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001167:Arteritis / Q000150:complications / Q000188:drug therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005858:Germany; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D015356:Retinal Artery Occlusion / Q000188:drug therapy* / Q000209:etiology; D012173:Retinitis / Q000150:complications / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
Br J Ophthalmol. 2008 May;92(5):588-93
18441166
Graefes Arch Clin Exp Ophthalmol. 2007 Mar;245(3):464-6; author reply 467-70
17119999
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001989
19160204
Ophthalmology. 1995 Dec;102(12):2029-34; discussion 2034-5
9098313
J Neuroimaging. 2007 Oct;17(4):339-43
17894624
Br J Ophthalmol. 2000 Aug;84(8):914-6
10906103
Arch Ophthalmol. 2003 Oct;121(10):1377-81
14557172
Am J Ophthalmol. 1992 Apr 15;113(4):429-34
1558118
Am J Ophthalmol. 2008 Nov;146(5):700-6
18718570
Br J Ophthalmol. 1980 Dec;64(12):913-7
7448144
Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):950-6
16372192
Am J Ophthalmol. 2008 Nov;146(5):631-4
18984082
J Fr Ophtalmol. 1984;7(11):711-6
6533162
Br J Ophthalmol. 2008 May;92(5):585-7
18441165
Acta Ophthalmol Suppl. 1971;109:1-95
4334005
Stroke. 1992 May;23(5):632-40
1579958
Stroke. 1992 May;23(5):641-5
1579959
Br J Ophthalmol. 1980 Nov;64(11):818-25
7426553
Ophthalmologe. 2006 Oct;103(10):898-900
16998653
Neuroradiology. 1993;35(8):600-5
8278042
Invest Ophthalmol Vis Sci. 1993 Jan;34(1):120-9
8425819
Ophthalmology. 2010 Jul;117(7):1367-75.e1
20609991
Circulation. 2007 May 22;115(20):e478-534
17515473
Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):137-42
18766368
Graefes Arch Clin Exp Ophthalmol. 2009 Apr;247(4):491-4
18989688
Klin Monbl Augenheilkd. 2000 Jul;217(1):30-6
10949814
Exp Eye Res. 2004 Mar;78(3):723-36
15106952
Ophthalmology. 1982 Jan;89(1):14-9
7070767
Am J Ophthalmol. 2005 Sep;140(3):376-91
16138997